Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Therapy01:28

Drug Therapy

401
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
401
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

1.2K
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
1.2K
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

1.2K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.2K
Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

774
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
774
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

663
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
663
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

2.0K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence of sleep-related symptoms in patients receiving methadone maintenance treatment: a systematic review and meta-analysis.

Addiction science & clinical practice·2026
Same author

Targeting Mu Opioid Receptor Neurons of the Habenula to Limit Naloxone Aversion.

Biological psychiatry·2026
Same author

Help-Seeking and Substance Use Among Police Staff After the 2018 Strasbourg Christmas Market Attack.

American journal of industrial medicine·2026
Same author

Protocol for a living systematic review of randomised controlled trials on the clinical efficacy of transcranial pulse stimulation in neurological and psychiatric conditions.

BMJ open·2026
Same author

Retention and Other Efficacy Outcomes With Long-Acting Injectable Buprenorphine (Buvidal<sup>®</sup>) in France: A National Retrospective Cross-Sectional Study (OPALE 2).

Substance use & addiction journal·2026
Same author

Passage of Time or Delay Signal at the Level of Milliseconds: A New Approach and a Selective Difficulty in Individuals With Schizophrenia.

Schizophrenia bulletin·2026

Related Experiment Video

Updated: Mar 31, 2026

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
09:29

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Published on: August 4, 2022

2.9K

Medications between psychiatric and addictive disorders.

Laurence Lalanne1, Pierre-Eric Lutz2, Benoit Trojak3

  • 1Translational Medicine and Neurogenetics, Institut de Génétique et de Biologie Molé-culaire et Cellulaire, INSERM U-964, CNRS UMR-7104, Université de Strasbourg, France; CHRU de Strasbourg-INSERM1114, Department of Psychiatry, University of Strasbourg, France.

Progress in Neuro-Psychopharmacology & Biological Psychiatry
|October 31, 2015
PubMed
Summary

New medications targeting shared neurobiological and cognitive pathways show promise for treating dual diagnosis (co-occurring psychiatric and substance use disorders). These innovative treatments offer potential benefits for clinical observation and patient care.

Keywords:
AddictionClozapineCognitionDepressionDual diagnosisMirtazapineModafinilPsychiatric disordersSchizophrenia

More Related Videos

Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression
07:58

Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression

Published on: February 24, 2023

975
Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice
07:31

Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice

Published on: January 7, 2019

8.8K

Related Experiment Videos

Last Updated: Mar 31, 2026

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
09:29

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Published on: August 4, 2022

2.9K
Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression
07:58

Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression

Published on: February 24, 2023

975
Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice
07:31

Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice

Published on: January 7, 2019

8.8K

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Epidemiological studies frequently show co-occurrence of psychiatric and substance use disorders, termed dual diagnosis.
  • Clinical observations revealed medication effects across these co-occurring disorders.
  • Shared neurobiological pathways and cognitive deficits in psychiatric and substance use disorders inform therapeutic development.

Purpose of the Study:

  • To review novel medications developed on neurobiological and cognitive rationales.
  • To assess the impact of these medications on both psychiatric and addictive disorders.
  • To highlight their clinical relevance for dual diagnosis.

Main Methods:

  • Review of scientific literature on medications targeting shared pathways.
  • Analysis of neurobiological and cognitive underpinnings of dual diagnosis treatments.
  • Synthesis of findings related to clinical observation and patient outcomes.

Main Results:

  • Identified unique medications with impact on both psychiatric and addictive disorders.
  • Highlighted the clinical interest and potential of these novel prescriptions.
  • Demonstrated the value for treating patients with dual diagnosis.

Conclusions:

  • Development of dual diagnosis medications enhances understanding of psychiatric and substance use disorders.
  • These medications are of significant interest for clinical practice and research.
  • Further research is warranted to fully explore their therapeutic potential.